Treatments for post-menopausal osteoporotic women, what's new? How can we manage long-term treatment?

被引：13

作者：

Herrero, Soledad ^{[1
]}

Pico, Yolanda ^{[1
]}

机构：

[1] Univ Valencia, Fac Pharm, Dept Prevent Med, Food & Environm Res Grp SAMA UV, Vicent Andres Estelles Ave, E-46100 Valencia, Spain

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 2016年 / 779卷

关键词：

Postmenopausal Osteoporosis; Long-term-Treatment; Bisphosphonate; Denosumab; Romosozumab; Cathepsin K; CATHEPSIN K INHIBITOR; VERTEBRAL FRACTURES; RANDOMIZED-TRIAL; PARATHYROID-HORMONE; STRONTIUM RANELATE; ORAL IBANDRONATE; HIP FRACTURE; ALENDRONATE; RISK; RISEDRONATE;

D O I：

10.1016/j.ejphar.2016.02.053

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Since the mid-1980s, postmenopausal osteoporosis (PMO) has been considered a serious public health concern because of the associated fractures. Pharmacological therapies that effectively reduce the number of fractures by improving bone mass have been and are being developed continuously. Most current agents inhibit bone loss by reducing bone resorption, but emerging therapies may increase bone mass by stimulating bone formation. Furthermore, nowadays, the most representative pharmaceuticals have been prescribed long enough to include the reporting of some adverse effects. This review discusses osteoporotic drugs that are approved or are under investigation for the treatment of post-menopausal women (PMW), paying particular attention to long-term treatments. (C) 2016 Elsevier B.V. All rights reserved.

引用

页码：8 / 21

页数：14

共 48 条

[1]

AEMPS, 2014, DRUG DESCR DRUG SAF

[2]

American College of Rheumatology, 2014, TER FORT TREATM OST

[3]

Amgen Ilt, 2014, ROM CLIN TRIALS

[4]

[Anonymous], 2014, CLIN GUID PREV TREAT

[5] Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].

Black, Dennis M. ;

Schwartz, Ann V. ;

Ensrud, Kristine E. ;

Cauley, Jane A. ;

Levis, Silvina ;

Quandt, Sara A. ;

Satterfield, Suzanne ;

Wallace, Robert B. ;

Bauer, Douglas C. ;

Palermo, Lisa ;

Wehren, Lois E. ;

Lombardi, Antonio ;

Santora, Arthur C. ;

Cummings, Steven R. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938

[6] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].

Black, DM ;

Cummings, SR ;

Karpf, DB ;

Cauley, JA ;

Thompson, DE ;

Nevitt, MC ;

Bauer, DC ;

Genant, HK ;

Haskell, WL ;

Marcus, R ;

Ott, SM ;

Torner, JC ;

Quandt, SA ;

Reiss, TF ;

Ensrud, KE .

LANCET, 1996, 348 (9041) :1535-1541

[7] Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].

Bone, HG ;

Hosking, D ;

Devogelaer, J ;

Tucci, JR ;

Emkey, RD ;

Tonino, RP ;

Rodriguez-Portales, JA ;

Downs, RW ;

Gupta, J ;

Santora, AC ;

Liberman, UA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199

[8] A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study [J].

Chesnut, CH ;

Silverman, S ;

Andriano, K ;

Genant, H ;

Gimona, A ;

Harris, S ;

Kiel, D ;

LeBoff, M ;

Maricic, M ;

Miller, P ;

Moniz, C ;

Peacock, M ;

Richardson, P ;

Watts, N ;

Baylink, D .

AMERICAN JOURNAL OF MEDICINE, 2000, 109 (04) :267-276

[9] Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis [J].

Chesnut, CH ;

Skag, A ;

Christiansen, C ;

Recker, R ;

Stakkestad, JA ;

Hoiseth, A ;

Felsenberg, D ;

Huss, H ;

Gilbride, J ;

Schimmer, RC ;

Delmas, PD .

JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1241-1249

[10] Bisphosphonate therapy for osteoporosis: The long and short of it [J].

Compston, Juliet E. ;

Bilezikian, John P. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (02) :240-242

← 1 2 3 4 5 →